Patents by Inventor Mahendra G. Dedhiya

Mahendra G. Dedhiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200268685
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 27, 2020
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Patent number: 10660868
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Suneel K Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G Dedhiya, Shashank Mahashabde
  • Publication number: 20180169082
    Abstract: Oral dosage forms comprising donepezil or a pharmaceutically acceptable salt thereof (e.g., donepezil hydrochloride) alone or in combination with a second active ingredient (e,g,, memantine hydrochloride or a pharmaceutically acceptable salt thereof) for the treatment of Alzheimer's disease are provided. The oral dosage forms comprise donepezil granules that may be sprinkled on food and can significantly improve compliance in patients with swallowing difficulty.
    Type: Application
    Filed: May 15, 2017
    Publication date: June 21, 2018
    Inventors: Mahendra G. Dedhiya, Kavita Vermani, Ashok Katdare
  • Publication number: 20170210742
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 27, 2017
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Veronique Ducandas, Alexandre Guiliani, Valerie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Patent number: 9695122
    Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 4, 2017
    Assignee: Forest Laboratories Holdings Ltd.
    Inventors: Melanie Simone Ronsheim, Saibaba Racha, Graham Richard Lawton, Shao Hong Zhou, Yuriy B. Kalyan, Michael Golden, David Milne, Alexander Telford, Janette Cherryman, Alistair Boyd, Andrew Phillips, Mahendra G. Dedhiya
  • Patent number: 9580424
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: February 28, 2017
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Publication number: 20170022160
    Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
    Type: Application
    Filed: February 10, 2016
    Publication date: January 26, 2017
    Inventors: Melanie Simone Ronsheim, Saibaba Racha, Graham Richard Lawton, Shao Hong Zhou, Yuriy B. Kalyan, Michael Golden, David Milne, Alexander Telford, Janette Cherryman, Alistair Boyd, Andrew Phillips, Mahendra G. Dedhiya
  • Publication number: 20160324803
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
  • Patent number: 9284314
    Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: March 15, 2016
    Assignee: Forest Laboratories Holdings Ltd.
    Inventors: Melanie Simone Ronsheim, Saibaba Racha, Graham Richard Lawton, Shao Hong Zhou, Yuriy B. Kalyan, Michael Golden, David Milne, Alexander Telford, Janette Cherryman, Alistair Boyd, Andrew Phillips, Mahendra G. Dedhiya
  • Patent number: 9259403
    Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: February 16, 2016
    Inventors: Rahul Surana, Mahendra G. Dedhiya
  • Publication number: 20160015638
    Abstract: The invention relates to stable pharmaceutical compositions comprising a glucokinase (GK) activator suitable for oral administration. The invention also relates to methods of making and using such pharmaceutical compositions.
    Type: Application
    Filed: August 31, 2015
    Publication date: January 21, 2016
    Inventors: Yun Mo, Mahendra G. Dedhiya, Anil Chhettry
  • Publication number: 20150258042
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
  • Publication number: 20150258031
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20150246920
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Application
    Filed: May 13, 2015
    Publication date: September 3, 2015
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Publication number: 20150238442
    Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
  • Publication number: 20150216849
    Abstract: Oral dosage forms comprising donepezil or a pharmaceutically acceptable salt thereof (e.g., donepezil hydrochloride) alone or in combination with a second active ingredient (e.g., memantine hydrochloride or a pharmaceutically acceptable salt thereof) for the treatment of Alzheimer's disease are provided. The oral dosage forms comprise donepezil granules that may be sprinkled on food and can significantly improve compliance in patients with swallowing difficulty.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Mahendra G. Dedhiya, Kavita Vermani, Ashok Katdare
  • Publication number: 20150196572
    Abstract: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.
    Type: Application
    Filed: March 4, 2015
    Publication date: July 16, 2015
    Inventors: Mahendra G. Dedhiya, Yigong Ge, Chun (Vernon) Jiang
  • Patent number: RE47333
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 2, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
  • Patent number: RE47350
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
  • Patent number: RE49110
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: June 21, 2022
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry